Funding will support the development of Company’s lead product candidate for autoimmune disease as well as novel constructs to treat other indications with significant unmet need.BURLINGAME, Calif., ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...

Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...

The shares of drug maker TG Therapeutics (TGTX) are climbing 9% today after the firm preannounced higher-than-expected 2024 ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

The antibody-drug conjugate (ADC), marketed by ADC Therapeutics under the brand name Zynlonta, received accelerated approval ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...

Telix Pharmaceuticals (ASX:TLX) enters into an asset purchase agreement with antibody engineering company ImaginAb.